title: Antinociceptive and anti-inflammatory properties of 7-hydroxycoumarin in experimental animal models: potential therapeutic for the control of inflammatory chronic pain.
abstract: OBJECTIVE
  In the present study we investigated the antinociceptive, anti-inflammatory and antipyretic effects of 7-hydroxycoumarin (7-HC) in animal models.
  
  
  METHODS
  The effects of oral 7-HC were tested against acetic acid-induced writhing, formalin test, tail flick test, complete Freund's adjuvant (CFA)-induced hypernociception, carrageenan-induced paw oedema, lipopolysaccharide-induced fever and the rota rod test.
  
  
  RESULTS
  7-HC (3-60 mg/kg) produced a dose-related antinociception against acetic acid-induced writhing in mice and in the formalin test. In contrast, treatment with 7-HC did not prevent thermal nociception in the tail flick test. A single treatment with 7-HC, 60 mg/kg, produced a long-lasting antinociceptive effect against CFA-induced hypernociception, a chronic inflammatory pain stimulus. Notably, at 60 mg/kg per day over 4 days the administration of 7-HC produced a continuous antinociceptive effect against CFA-induced hypernociception. 7-HC (30-120 mg/kg) produced anti-inflammatory and antipyretic effects against carrageenan-induced inflammation and lipopolysaccharide-induced fever, respectively. Moreover, 7-HC was found to be safe with respect to ulcer induction. In the rota rod test, 7-HC-treated mice did not show any motor performance alterations.
  
  
  CONCLUSIONS
  The prolonged antinociceptive and anti-inflammatory effects of 7-HC, in association with its low ulcerogenic activity, indicate that this molecule might be a good candidate for development of new drugs for the control of chronic inflammatory pain and fever.
authors.affiliation: Oswaldo Cruz Foundation, Brazil.
authors.forename: Taís A de Almeida
authors.initials: TA
authors.lastname: Barros
authors.forename: Luis A R
authors.initials: LA
authors.lastname: de Freitas
authors.forename: José M B
authors.initials: JM
authors.lastname: Filho
authors.forename: Xirley P
authors.initials: XP
authors.lastname: Nunes
authors.forename: Ana M
authors.initials: AM
authors.lastname: Giulietti
authors.forename: Glória E
authors.initials: GE
authors.lastname: de Souza
authors.forename: Ricardo R
authors.initials: RR
authors.lastname: dos Santos
authors.forename: Milena B P
authors.initials: MB
authors.lastname: Soares
authors.forename: Cristiane F
authors.initials: CF
authors.lastname: Villarreal
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002908:Chronic Disease; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004487:Edema / Q000188:drug therapy; D005334:Fever / Q000188:drug therapy; D007249:Inflammation / Q000188:drug therapy*; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D010146:Pain / Q000188:drug therapy*; D010147:Pain Measurement; D051381:Rats; D017208:Rats, Wistar; D014468:Umbelliferones / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D014468:Umbelliferones; C031477:7-hydroxycoumarin